ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements
Kilitch Drugs(I) Ltd reported revenue from operations of ₹50.2 Cr (+2.7% YoY) and net profit of ₹1.4 Cr (-82.5% YoY) for Q2 FY27.
Kilitch Drugs will hold a board meeting on 6 November 2026 to consider unaudited quarterly and half-year results. The trading window stays closed until 48 hours after disclosure.
Kilitch Drugs' EGM notice seeks shareholder approval for selling its Ethiopian material subsidiary and converting subsidiary debt into equity. It also proposes two independent director appointments.
Kilitch Drugs will divest its entire Ethiopian subsidiary stake to HarmeeCare for US$14 million (~₹131.6 Crore). Proceeds will fund debt repayment and Pen plant expansion.
Kilitch Drugs will divest its 100% stake in subsidiary Kilitch Estro Biotech PLC for USD 12.855 million (approx. ₹120.84 Crore).
Kilitch Drugs' Non-Executive Independent Director Mr. Venkita Subramanian Rajan resigned effective 21 Oct 2026. He also stepped down from the Audit, NCR, and SRC Committees citing personal commitments.
Kilitch Drugs (India) Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026.
Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.
Kilitch Drugs filed its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Rights Issue proceeds of Rs. 49.92 Crore.
Kilitch Drugs(I) Ltd reported revenue from operations of ₹44.9 Cr (+4.2% YoY) and net profit of ₹2 Cr (-13.0% YoY) for Q1 FY27.
Kilitch Drugs (India) Ltd has scheduled a board meeting for August 13, 2026. The board will consider and approve unaudited financial results for the June quarter.
Kilitch Drugs submitted its Annual Report for FY 2025-26 and the notice for the 34th Annual General Meeting to the stock exchanges.
Kilitch Drugs (India) Limited has re-appointed Arivind Kumar & Co. as its Cost Auditor for a 12-month term.
Kilitch Drugs (India) Ltd announced its 34th Annual General Meeting scheduled for August 27, 2026, along with relevant book closure dates. The board also re-appointed cost auditors.
Kilitch Drugs (India) Limited submitted its Annual Secretarial Compliance Report for the financial year 2026. This mandatory regulatory filing confirms the company's adherence to SEBI governance standards.
Kilitch Drugs (India) Ltd will hold a Board Meeting on May 15, 2026, to consider and approve audited standalone and consolidated financial results for the year ended March 31, 2026. The company's trading window remains closed until 48 hours after the results are disclosed.